Nightstar Therapeutics Limited (NITE) received a Hold rating and a $25.50 price target from Mizuho Securities analyst Difei Yang today. The company’s shares closed yesterday at $25.18.
Yang noted:
“We believe the valuation is reasonable for several reasons: The 70% premium offered is below previous acquisitions in the gene therapy space including ~88% in the Novartis (NVS, non-rated)/AveXis transaction and 122% in the recent Roche (RHHBY, Not-rated)/Spark transaction.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.6% and a 50.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.
Nightstar Therapeutics Limited has an analyst consensus of Moderate Buy, with a price target consensus of $25.25, a 0.3% upside from current levels. In a report released yesterday, Cantor Fitzgerald also downgraded the stock to Hold with a $25.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29.55 and a one-year low of $9.59. Currently, Nightstar Therapeutics Limited has an average volume of 280.6K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.
